SCHEMBL6187899

SCHEMBL6187899

Cc1ccc2oc(=O)cc(NC3CCN(C/C=C/c4ccccc4)CC3)c2c1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 8/20 0.80
MAPT P10636 4/20 0.66
KMT2A Q03164 2/20 0.66
KCNH2 Q12809 2/20 0.55
LMNA P02545 5/20 0.51
ALDH1A1 P00352 3/20 0.51
USP2 O75604 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
MAPK1 P28482 1/20 0.51
TSHR P16473 3/20 0.50
KDM4E B2RXH2 3/20 0.49
POLB P06746 1/20 0.49
HTT P42858 1/20 0.49
ANXA2 P07355 2/20 0.46
S100A10 P60903 2/20 0.46
P4HB P07237 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6187903 1.00 MCHR1 (0.80) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6185918 0.93 MCHR1 (0.75) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6185911 0.93 MCHR1 (0.75) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6190413 0.91 MCHR1 (0.73) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6190416 0.91 MCHR1 (0.73) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6188187 0.89 MCHR1 (1.00) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6188188 0.89 MCHR1 (1.00) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6191847 0.89 MCHR1 (0.80) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6185618 0.89 MCHR1 (0.80) MCHR1MAPTKMT2AKCNH2LMNA
SCHEMBL6189419 0.89 MCHR1 (1.00) MCHR1MAPTKMT2AKCNH2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US claimed
EP-1534703-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR ABBOTT LABORATORIES (US) 2005-06-01 EP claimed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US claimed
WO-2003106452-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-24 WO claimed
US-6921821-B2 Antagonists of melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
EP-1534703-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR ABBOTT LABORATORIES (US) 2005-06-01 EP disclosed
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-06-03 US disclosed
WO-2003106452-A2 ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106645-A1 Antagonists of melanin concentrating hormone receptor MCHR1, MCHR2, MC1R MCHR1 1/4885MAPT 4185/4885KMT2A 1796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.